House dust mite allergen-specific immunoglobulin E and immunoglobulin G (HDM-specific IgE and IgG)

Polyclonal allergen-specific IgE and IgG antibodies against Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f) are the primary immunological components involved in house dust mite (HDM) allergy. IgE antibodies specific to HDM proteins bind to high-affinity receptors on mast cells and basophils; upon subsequent exposure to the allergen, these antibodies are cross-linked, triggering the release of inflammatory mediators such as histamine and leukotrienes [1]. This process is the hallmark of Type I hypersensitivity and drives the clinical manifestations of allergic asthma and rhinitis [2]. In contrast, allergen-specific IgG antibodies, particularly the IgG4 subclass, serve a protective role by acting as 'blocking antibodies' that intercept allergens before they can reach cell-bound IgE [3]. Therapeutic interventions either target the IgE molecule directly to prevent its binding to effector cells or utilize allergen immunotherapy to modulate the polyclonal antibody profile, favoring a higher IgG4 to IgE ratio to induce clinical tolerance [4]. Monitoring these antibody levels is essential for both the diagnosis of HDM sensitivity and the evaluation of treatment efficacy in clinical practice [5]. Sources: [1] StatPearls. House Dust Mite Allergy. https://www.ncbi.nlm.nih.gov/books/NBK560737/ [2] Journal of Allergy and Clinical Immunology. Mechanisms of allergen immunotherapy. https://doi.org/10.1016/j.jaci.2017.06.009 [3] EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic rhinitis. https://onlinelibrary.wiley.com/doi/full/10.1111/all.13316 [4] Novartis/Genentech. Xolair (omalizumab) Prescribing Information. https://www.gene.com/download/pdf/xolair_prescribing.pdf [5] Allergy, Asthma & Immunology Research. Biomarkers in Allergen Immunotherapy. https://doi.org/10.4168/aair.2016.8.5.375

Other names

Anti-Dermatophagoides pteronyssinus antibodiesAnti-Dermatophagoides farinae antibodiesHDM-specific antibodiesDer p and Der f specific IgE/IgGHouse dust mite specific immunoglobulins

Drugs like Omalizumab bind to the Cε3 domain of free IgE, preventing its interaction with high-affinity FcεRI receptors on mast cells and basophils, thereby inhibiting the allergic cascade. Allergen immunotherapy (AIT) works by repeatedly exposing the patient to HDM proteins to induce a shift from an IgE-mediated Th2 response to a regulatory T cell (Treg) response, which promotes the production of 'blocking' IgG4 antibodies that compete with IgE for allergen binding.